Skip to Content

Capmatinib Side Effects

Medically reviewed by Drugs.com. Last updated on June 1, 2020.

For the Consumer

Applies to capmatinib: oral tablet

Warning

Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • new or worsening cough, chest pain, trouble breathing;

  • fever, cough with mucus;

  • severe ongoing nausea and vomiting; or

  • liver problems--swelling around your midsection, right-sided upper stomach pain, vomiting, confusion, weakness, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects may include:

  • trouble breathing;

  • nausea, vomiting, decreased appetite;

  • feeling weak or tired;

  • abnormal liver function tests; or

  • swelling in your hands or feet.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For Healthcare Professionals

Applies to capmatinib: oral tablet

Hematologic

Very common (10% or more): Lymphocytes decreased (44%), hemoglobin decreased (24%), leukocytes decreased (23%)[Ref]

Musculoskeletal

Very common (10% or more): Noncardiac chest pain (e.g., chest discomfort, musculoskeletal chest pain, noncardiac chest pain, chest pain) (15%), back pain (14%)[Ref]

Metabolic

Very common (10% or more): Albumin decreased (68%), creatinine increased (62%), alanine aminotransferase increased (37%), alkaline phosphatase increased (32%), amylase increased (31%), gamma-glutamyltransferase increased (29%), lipase increased (26%), aspartate aminotransferase increased (25%), sodium decreased (23%), phosphate decreased (23%), glucose decreased (21%), weight loss (10%)[Ref]

Respiratory

Very common (10% or more): Dyspnea (24%), cough (16%)

Common (1% to 10%): ILD/pneumonitis[Ref]

Other

Very common (10% or more): Peripheral edema (e.g., peripheral swelling, peripheral edema, fluid overload) (52%), fatigue/asthenia (32%), pyrexia/increased body temperature (14%)[Ref]

Renal

Very common (10% or more):

Common (1% to 10%): Acute kidney injury (including renal failure)[Ref]

Dermatologic

Common (1% to 10%): Pruritus (allergic and generalized), cellulitis, urticaria[Ref]

Gastrointestinal

Very common (10% or more): Nausea (44%), vomiting (28%), constipation (18%), diarrhea (18%)

Common (1% to 10%): Acute pancreatitis[Ref]

References

1. "Product Information. Tabrecta (capmatinib)." Novartis Pharmaceuticals, East Hanover, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.